MX2023011362A - Anticuerpos multiespecificos novedosos. - Google Patents
Anticuerpos multiespecificos novedosos.Info
- Publication number
- MX2023011362A MX2023011362A MX2023011362A MX2023011362A MX2023011362A MX 2023011362 A MX2023011362 A MX 2023011362A MX 2023011362 A MX2023011362 A MX 2023011362A MX 2023011362 A MX2023011362 A MX 2023011362A MX 2023011362 A MX2023011362 A MX 2023011362A
- Authority
- MX
- Mexico
- Prior art keywords
- lag
- present disclosure
- multispecific antibody
- binds
- multispecific antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2027891 | 2021-03-31 | ||
| PCT/NL2022/050174 WO2022211625A1 (en) | 2021-03-31 | 2022-03-30 | Novel multispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011362A true MX2023011362A (es) | 2023-10-05 |
Family
ID=76035095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011362A MX2023011362A (es) | 2021-03-31 | 2022-03-30 | Anticuerpos multiespecificos novedosos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240309115A1 (https=) |
| EP (1) | EP4314061A1 (https=) |
| JP (1) | JP2026026084A (https=) |
| KR (1) | KR20230165256A (https=) |
| CN (2) | CN118165116A (https=) |
| AU (1) | AU2022251985A1 (https=) |
| BR (1) | BR112023020141A2 (https=) |
| CA (1) | CA3213796A1 (https=) |
| IL (1) | IL307332A (https=) |
| MX (1) | MX2023011362A (https=) |
| PH (1) | PH12023552704A1 (https=) |
| TW (1) | TW202302630A (https=) |
| WO (1) | WO2022211625A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220380440A1 (en) * | 2018-12-31 | 2022-12-01 | Merus N.V. | Truncated multivalent multimers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| BR112019005895A2 (pt) | 2016-09-23 | 2019-06-11 | Merus N.V. | moléculas de ligação que modulam uma atividade biológica expressa por uma célula |
| EA202090003A1 (ru) | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка |
| EA202090005A1 (ru) | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Антитела, модулирующие биологическую активность, проявляемую клеткой |
| KR102666754B1 (ko) * | 2018-08-21 | 2024-05-17 | 에이비엘바이오 주식회사 | 항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도 |
| KR20220008316A (ko) * | 2019-05-14 | 2022-01-20 | 에프-스타 테라퓨틱스 리미티드 | Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법 |
| EP3983450A4 (en) * | 2019-06-12 | 2023-07-05 | Nanjing GenScript Biotech Co., Ltd. | ANTI-PD-L1/ANTI-LAG-3 PROTEINS WITH MULTIPLE ANTIGEN BINDING AND METHODS FOR THEIR USE |
-
2022
- 2022-03-30 AU AU2022251985A patent/AU2022251985A1/en active Pending
- 2022-03-30 WO PCT/NL2022/050174 patent/WO2022211625A1/en not_active Ceased
- 2022-03-30 EP EP22714634.7A patent/EP4314061A1/en active Pending
- 2022-03-30 TW TW111112288A patent/TW202302630A/zh unknown
- 2022-03-30 MX MX2023011362A patent/MX2023011362A/es unknown
- 2022-03-30 CN CN202410306860.1A patent/CN118165116A/zh active Pending
- 2022-03-30 BR BR112023020141A patent/BR112023020141A2/pt not_active Application Discontinuation
- 2022-03-30 KR KR1020237034870A patent/KR20230165256A/ko active Pending
- 2022-03-30 US US18/553,114 patent/US20240309115A1/en active Pending
- 2022-03-30 PH PH1/2023/552704A patent/PH12023552704A1/en unknown
- 2022-03-30 CN CN202280026434.1A patent/CN117157323A/zh active Pending
- 2022-03-30 IL IL307332A patent/IL307332A/en unknown
- 2022-03-30 CA CA3213796A patent/CA3213796A1/en active Pending
-
2025
- 2025-10-24 JP JP2025179886A patent/JP2026026084A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118165116A (zh) | 2024-06-11 |
| KR20230165256A (ko) | 2023-12-05 |
| AU2022251985A1 (en) | 2023-10-19 |
| BR112023020141A2 (pt) | 2023-11-28 |
| TW202302630A (zh) | 2023-01-16 |
| US20240309115A1 (en) | 2024-09-19 |
| CA3213796A1 (en) | 2022-10-06 |
| PH12023552704A1 (en) | 2024-02-19 |
| CN117157323A (zh) | 2023-12-01 |
| IL307332A (en) | 2023-11-01 |
| EP4314061A1 (en) | 2024-02-07 |
| WO2022211625A1 (en) | 2022-10-06 |
| JP2024511871A (ja) | 2024-03-15 |
| JP2026026084A (ja) | 2026-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552122A1 (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
| MX2023005375A (es) | Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. | |
| HRP20251020T1 (hr) | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 | |
| WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
| WO2022032004A3 (en) | Anti-claudin 18.2 multi-specific antibodies and uses thereof | |
| ZA202210626B (en) | Anti-cd137 constructs, multispecific antibody and uses thereof | |
| NZ610091A (en) | Antibodies | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| PH12022500027A1 (en) | Antibodies binding to cd3 | |
| MX2023009715A (es) | Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo. | |
| MX2022014224A (es) | Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2. | |
| WO2022031710A3 (en) | Multispecific binding agents and uses thereof | |
| WO2019183093A8 (en) | High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof | |
| MX2023015442A (es) | Tratamiento de la enfermedad cardiovascular con proteínas de unión a antígeno trem-1. | |
| PH12023552704A1 (en) | Novel multispecific antibodies | |
| MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
| AR109770A1 (es) | ANTICUERPOS DEL RECEPTOR II DE TGF-b | |
| WO2022251695A8 (en) | Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd) | |
| CR20230464A (es) | Dominios de unión a pd-1 novedosos. | |
| PH12023552740A1 (en) | Multispecific Binding Moieties Comprising Novel PD-1 Binding Domains | |
| MX2026001284A (es) | Anticuerpos anti-gprc5d y composiciones | |
| MX2026000164A (es) | Anticuerpos pd-l1xcd28 biespecificos y metodos de uso de los mismos | |
| MX2026000166A (es) | Anticuerpos biespecificos pd-l1x4-1bb y metodos de uso de los mismos | |
| MX2023009716A (es) | Anticuerpo de dominio individual contra ligando de muerte programada 1 (pd-l1) y uso del mismo. | |
| MX2025008617A (es) | Agentes que se unen a nkg2a y pd-l1 y usos de estos |